通过向MYC/ABCF1轴,NTRK2促进肺腺癌的恶性进展和帕克利塔塞尔耐药性
Rongrong Cui1, Yuanyuan Wang1, Yao Yao1
1Department of Endocrinology and International Joint Research Center for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Translational oncology
|January 7, 2026
概括
通过激活NTRK2/MYC/ABCF1通路,神经营养受体氨酸激酶2 (NTRK2) 驱动肺腺癌 (LUAD) 的进展和帕克利塔塞尔耐药性. 向NTRK2可能会在LUAD患者中克服化学抵抗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肺腺癌 (LUAD) 是一种主要的癌症亚型,化学抵抗导致不良结果.
- 神经营养受体氨酸激酶2 (NTRK2) 在LUAD瘤发生和帕克利塔塞尔耐药性的作用尚未完全理解.
研究的目的:
- 调查NTRK2在LUAD进展中的作用及其对帕克利塔克塞尔耐药性的贡献.
- 阐明NTRK2-介导化学抵抗的潜在分子机制.
主要方法:
- 在LUAD组织中分析NTRK2表达和与患者结果的相关性.
- 在体外功能测定 (siRNA敲击,过度表达) 在LUAD细胞中.
- 在体内异种移植小鼠模型,以评估瘤生长和药物反应.
- 研究包括MAPK/ERK,PI3K/AKT和MYC在内的信号通路.
主要成果:
- 在LUAD组织中,NTRK2显著上调,并且与帕克利塔塞尔化疗后复发有关.
- NTRK2 Knockdown 抑制了 LUAD 细胞增殖,在体外增强了帕克利塔塞尔的敏感性,并在体内抑制了瘤的生长.
- 过度表达NTRK2促进了LUAD细胞恶性病变,并降低了对帕克利塔塞尔的反应.
- NTRK2激活了MAPK/ERK和PI3K/AKT通路,导致MYC上调和随后的ABCF1激活,促进化学抵抗.
结论:
- 在LUAD中,NTRK2充当瘤原体驱动剂,通过NTRK2/MYC/ABCF1信号轴赋予帕克利塔塞尔耐药性.
- NTRK2及其下游目标代表了克服LUAD化学抵抗的潜在治疗目标.
更多相关视频
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K


